Early Data for CRX100 Pave Way for Potential Combinations in Recurrent, Platinum-Resistant Ovarian Cancer

Oliver Dorigo, MD, PhD, discusses the investigation of CRX100 in patients with recurrent, platinum-resistant ovarian cancer.

Related Keywords

Stanford ,California ,United States ,Oliver Dorigo ,Mary Lake Polan Gynecologic Oncology Research Laboratory ,Division Of Gynecologic Oncology ,Stanford Gynecologic Oncology Clinical Care Program ,Stanford Gynecologic Oncology Fellowship ,Stanford Clinical Research Group ,Gynecologic Cancer Trials ,Stanford Obstetrics ,Gynecologic Oncology ,Recurrent Ovarian Cancer ,Go Annual Meeting On Womens Cancer ,Rx100 ,Platinum Resistant ,